MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene. 2018

Jisun Kim, and Felipe C Geyer, and Luciano G Martelotto, and Charlotte Ky Ng, and Raymond S Lim, and Pier Selenica, and Anqi Li, and Fresia Pareja, and Nicola Fusco, and Marcia Edelweiss, and Rahul Kumar, and Rodrigo Gularte-Merida, and Andre N Forbes, and Ekta Khurana, and Odette Mariani, and Sunil Badve, and Anne Vincent-Salomon, and Larry Norton, and Jorge S Reis-Filho, and Britta Weigelt
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Breast adenoid cystic carcinoma (AdCC), a rare type of triple-negative breast cancer, has been shown to be driven by MYB pathway activation, most often underpinned by the MYB-NFIB fusion gene. Alternative genetic mechanisms, such as MYBL1 rearrangements, have been reported in MYB-NFIB-negative salivary gland AdCCs. Here we report on the molecular characterization by massively parallel sequencing of four breast AdCCs lacking the MYB-NFIB fusion gene. In two cases, we identified MYBL1 rearrangements (MYBL1-ACTN1 and MYBL1-NFIB), which were associated with MYBL1 overexpression. A third AdCC harboured a high-level MYB amplification, which resulted in MYB overexpression at the mRNA and protein levels. RNA-sequencing and whole-genome sequencing revealed no definite alternative driver in the fourth AdCC studied, despite high levels of MYB expression and the activation of pathways similar to those activated in MYB-NFIB-positive AdCCs. In this case, a deletion encompassing the last intron and part of exon 15 of MYB, including the binding site of ERG-1, a transcription factor that may downregulate MYB, and the exon 15 splice site, was detected. In conclusion, we demonstrate that MYBL1 rearrangements and MYB amplification probably constitute alternative genetic drivers of breast AdCCs, functioning through MYBL1 or MYB overexpression. These observations emphasize that breast AdCCs probably constitute a convergent phenotype, whereby activation of MYB and MYBL1 and their downstream targets can be driven by the MYB-NFIB fusion gene, MYBL1 rearrangements, MYB amplification, or other yet to be identified mechanisms. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D003528 Carcinoma, Adenoid Cystic Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed) Cylindroma,Adenocystic Carcinoma,Adenocystic Carcinomas,Adenoid Cystic Carcinoma,Adenoid Cystic Carcinomas,Carcinoma, Adenocystic,Carcinomas, Adenocystic,Carcinomas, Adenoid Cystic,Cylindromas,Cystic Carcinoma, Adenoid,Cystic Carcinomas, Adenoid
D005260 Female Females
D005784 Gene Amplification A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication. Amplification, Gene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015321 Gene Rearrangement The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development. DNA Rearrangement,DNA Rearrangements,Gene Rearrangements,Rearrangement, DNA,Rearrangement, Gene,Rearrangements, DNA,Rearrangements, Gene
D015514 Oncogene Proteins, Fusion The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin. Chimeric Oncogene Proteins,Chimeric Proteins, Oncogene,Fusion Proteins, Oncogene,Oncogene Fusion Proteins,Oncogene Proteins, Chimeric,Fusion Oncogene Proteins,Oncogene Chimeric Proteins,Proteins, Chimeric Oncogene,Proteins, Fusion Oncogene,Proteins, Oncogene Chimeric,Proteins, Oncogene Fusion

Related Publications

Jisun Kim, and Felipe C Geyer, and Luciano G Martelotto, and Charlotte Ky Ng, and Raymond S Lim, and Pier Selenica, and Anqi Li, and Fresia Pareja, and Nicola Fusco, and Marcia Edelweiss, and Rahul Kumar, and Rodrigo Gularte-Merida, and Andre N Forbes, and Ekta Khurana, and Odette Mariani, and Sunil Badve, and Anne Vincent-Salomon, and Larry Norton, and Jorge S Reis-Filho, and Britta Weigelt
February 2016, Clinical cancer research : an official journal of the American Association for Cancer Research,
Jisun Kim, and Felipe C Geyer, and Luciano G Martelotto, and Charlotte Ky Ng, and Raymond S Lim, and Pier Selenica, and Anqi Li, and Fresia Pareja, and Nicola Fusco, and Marcia Edelweiss, and Rahul Kumar, and Rodrigo Gularte-Merida, and Andre N Forbes, and Ekta Khurana, and Odette Mariani, and Sunil Badve, and Anne Vincent-Salomon, and Larry Norton, and Jorge S Reis-Filho, and Britta Weigelt
October 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Jisun Kim, and Felipe C Geyer, and Luciano G Martelotto, and Charlotte Ky Ng, and Raymond S Lim, and Pier Selenica, and Anqi Li, and Fresia Pareja, and Nicola Fusco, and Marcia Edelweiss, and Rahul Kumar, and Rodrigo Gularte-Merida, and Andre N Forbes, and Ekta Khurana, and Odette Mariani, and Sunil Badve, and Anne Vincent-Salomon, and Larry Norton, and Jorge S Reis-Filho, and Britta Weigelt
November 2017, Histopathology,
Jisun Kim, and Felipe C Geyer, and Luciano G Martelotto, and Charlotte Ky Ng, and Raymond S Lim, and Pier Selenica, and Anqi Li, and Fresia Pareja, and Nicola Fusco, and Marcia Edelweiss, and Rahul Kumar, and Rodrigo Gularte-Merida, and Andre N Forbes, and Ekta Khurana, and Odette Mariani, and Sunil Badve, and Anne Vincent-Salomon, and Larry Norton, and Jorge S Reis-Filho, and Britta Weigelt
November 2015, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Jisun Kim, and Felipe C Geyer, and Luciano G Martelotto, and Charlotte Ky Ng, and Raymond S Lim, and Pier Selenica, and Anqi Li, and Fresia Pareja, and Nicola Fusco, and Marcia Edelweiss, and Rahul Kumar, and Rodrigo Gularte-Merida, and Andre N Forbes, and Ekta Khurana, and Odette Mariani, and Sunil Badve, and Anne Vincent-Salomon, and Larry Norton, and Jorge S Reis-Filho, and Britta Weigelt
February 2024, Gynecologic oncology,
Jisun Kim, and Felipe C Geyer, and Luciano G Martelotto, and Charlotte Ky Ng, and Raymond S Lim, and Pier Selenica, and Anqi Li, and Fresia Pareja, and Nicola Fusco, and Marcia Edelweiss, and Rahul Kumar, and Rodrigo Gularte-Merida, and Andre N Forbes, and Ekta Khurana, and Odette Mariani, and Sunil Badve, and Anne Vincent-Salomon, and Larry Norton, and Jorge S Reis-Filho, and Britta Weigelt
April 2022, Cancers,
Jisun Kim, and Felipe C Geyer, and Luciano G Martelotto, and Charlotte Ky Ng, and Raymond S Lim, and Pier Selenica, and Anqi Li, and Fresia Pareja, and Nicola Fusco, and Marcia Edelweiss, and Rahul Kumar, and Rodrigo Gularte-Merida, and Andre N Forbes, and Ekta Khurana, and Odette Mariani, and Sunil Badve, and Anne Vincent-Salomon, and Larry Norton, and Jorge S Reis-Filho, and Britta Weigelt
July 2011, The Journal of pathology,
Jisun Kim, and Felipe C Geyer, and Luciano G Martelotto, and Charlotte Ky Ng, and Raymond S Lim, and Pier Selenica, and Anqi Li, and Fresia Pareja, and Nicola Fusco, and Marcia Edelweiss, and Rahul Kumar, and Rodrigo Gularte-Merida, and Andre N Forbes, and Ekta Khurana, and Odette Mariani, and Sunil Badve, and Anne Vincent-Salomon, and Larry Norton, and Jorge S Reis-Filho, and Britta Weigelt
February 2016, Cancer discovery,
Jisun Kim, and Felipe C Geyer, and Luciano G Martelotto, and Charlotte Ky Ng, and Raymond S Lim, and Pier Selenica, and Anqi Li, and Fresia Pareja, and Nicola Fusco, and Marcia Edelweiss, and Rahul Kumar, and Rodrigo Gularte-Merida, and Andre N Forbes, and Ekta Khurana, and Odette Mariani, and Sunil Badve, and Anne Vincent-Salomon, and Larry Norton, and Jorge S Reis-Filho, and Britta Weigelt
October 2019, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Jisun Kim, and Felipe C Geyer, and Luciano G Martelotto, and Charlotte Ky Ng, and Raymond S Lim, and Pier Selenica, and Anqi Li, and Fresia Pareja, and Nicola Fusco, and Marcia Edelweiss, and Rahul Kumar, and Rodrigo Gularte-Merida, and Andre N Forbes, and Ekta Khurana, and Odette Mariani, and Sunil Badve, and Anne Vincent-Salomon, and Larry Norton, and Jorge S Reis-Filho, and Britta Weigelt
October 2010, Clinical cancer research : an official journal of the American Association for Cancer Research,
Copied contents to your clipboard!